Biontech to avoid big acquisitions despite billions on the bottom line

Although the pandemic proved very prosperous for Biontech, giving the company new means in the shape of billion-euro profits, it won’t be spending its wealth on any big acquisitions, but instead smaller purchases and partnerships.

Photo: Biontech/PR

Times have changed for German Biontech, which became very wealthy from sales of its vaccines during the Covid-19 pandemic.

Alone in 2021, the company booked profits of EUR 10.3bn, and the company’s new financial situation has given husband and wife Ugur Sahin and Özlem Türeci, Biontech’s CEO and chief medical officer, respectively, completely new options.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs